Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly's Taltz (ixekizumab) has been approved in the US for moderate-to-severe plaque psoriasis, along with Teva's asthma drug Cinqair (reslizumab). The US Food and Drug Administration today ...

Teva Pharmaceuticals’ TEV-479 (olanzapine ... in 2009. It is marketed by Eli Lilly as Zyprexa and a longer-acting version ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab ... unapproved therapies such as Botox and anti-seizure medication. Teva’s CGRP drug Ajovy (fremanezumab) was approved by the FDA ...

Eli Lilly and Company LLY announced that the FDA ... Sanofi SNY in-licensed rights to jointly develop and commercialize Teva Pharmaceutical’s IBD candidate, duvakitug, an anti-TL1A therapy ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...